Clinical Trial Update: Transition to Rebif New Formulation [Phase 3]

View source ↗

Summary

Phase 3 trial update on transitioning to a new Rebif formulation for relapsing multiple sclerosis; results were posted in July 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Relapsing Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2010-07-26